Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data.

Singh, Ambrish; Hussain, Salman; Jha, Robin; Jayraj, Aarthi S; Klugar, Miloslav; Antony, Benny

Singh, Ambrish; Hussain, Salman; Jha, Robin; Jayraj, Aarthi S; Klugar, Miloslav; Antony, Benny.

Affiliation

Singh A; Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Hussain S; Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Jha R; Health Outcome Researcher, Independent, New Delhi, India.
Jayraj AS; Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Klugar M; Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
Antony B; Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

J Evid Based Med ; 14(4): 278-280, 2021 Dec.

Article in En | MEDLINE | ID: mdl-34643998

Subject(s)

Carcinoma, Hepatocellular; Liver Neoplasms; Carcinoma, Hepatocellular/epidemiology; Humans; Liver Neoplasms/epidemiology; Proton Pump Inhibitors/adverse effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Etiology_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: J Evid Based Med Year: 2021 Document type: Article Affiliation country: Australia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google